May 20th 2024
In recognition of Skin Cancer Awareness Month, Dermatology Times is reviewing research and strides in skin cancer treatment over the last decade.
Advances In: Integrating New Treatment Options into Management Plans for Patients with Moderate-to-Severe Atopic Dermatitis
View More
Medical Crossfire®: Maximizing Patient Outcomes in Shingles – Are You Leveraging Guideline Based Care?
View More
"REEL" Time Patient Counseling™: Integrating Biosimilars into the Clinical Conversation
View More
PER Skin Summit: Optimizing Diagnosis and Individualizing Management of Hidradenitis Suppurativa
View More
Community Practice Connections™: 19th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
View More
Expert Illustrations & Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)
View More
Cancer Summaries and Commentaries™: Clinical Updates in Melanoma from Philadelphia
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Dermatopathology sits in healthcare reform crosshairs
August 11th 2014If dermatologists don’t more effectively police themselves, experts say, they may lose their ability to perform in-office dermatopathology. Dermatopathology also faces competitive pressures and aggressive fee reductions, these experts add.
Celebrate the community while strengthening your practice
July 16th 2014When was the last time you got really excited about dermatology? I mean, in your bones, core-shaking, vitality-restoring, conquer the universe type of elation. If the answer is “Well, I can’t remember the last time.” or worse yet, “Maybe never?” then perhaps it is time to throw a party.
The role of the dermatologist in diagnosing, managing advanced basal cell carcinoma
July 15th 2014Advanced basal cell carcinoma is a term whose frequency of usage has increased recently, in part, due to the introduction of the Hedgehog pathway inhibitor, vismodegib. Advanced basal cell carcinoma (aBCC) is comprised of two subtypes of BCC associated with significant morbidity and mortality, locally advanced BCC (laBCC) and metastatic BCC (metBCC).
Electronic brachytherapy allows collaboration between dermatologists, radiation oncologists
July 7th 2014Electronic surface brachytherapy allows dermatologists to offer patients another safe, effective option for nonmelanoma skin cancer (NMSC), many experts say. And if the specialty doesn’t seize the opportunity, they add, it might lose some skin cancer treatments to radiation oncologists.
Smoothened inhibitors provide new options for BCC treatment
June 17th 2014Since the dawn of smoothened inhibitors, patients with locally advanced and metastatic basal cell carcinoma (BCC) now have a new and effective treatment alternative beyond the traditional and less optimal treatment approaches such as surgery and radiotherapy.
Predictive risk hierarchy for NMSC recurrence guides treatment strategies
May 19th 2014A recent study suggests that the most important predictive factors of recurrence for nonmelanoma skin cancers (NMSC) following radiotherapy include immunosuppression, age of the patient, tumor size as well as the treatment modality used.
Margin comments in nevi histology reports impact re-excision rates
May 1st 2014Histological reports on atypical or dysplastic nevi that include margin comments appear to have a significant impact on how the clinician will proceed regarding the potential re-excision of lesions, according to a recent literature review.
Molecular techniques explain potential nevoid pathways to melanoma
May 1st 2014Many of the current definitions of skin diseases used in dermatology have changed and morphed over the years, as clinicians learn more and amass volumes of new information regarding many different features, characteristics and associations of dermatologic diseases.
Novel strategies minimize actinic keratoses treatment burdens
May 1st 2014Field therapy in patients with multiple facial actinic keratoses (AKs) is important for preventing the development of new, clinically visible lesions and squamous cell carcinoma. Yet, for a number of reasons, including the need for prolonged topical treatment and poor tolerability, field therapy is widely underused.